Feed PALI
PA

Palisade Bio, Inc. PALI · NASDAQ

$1.11 -4.74% (-$0.06)

Market cap
$192.6M
Enterprise value
$67.4M
P/E
-
Forward P/E
-
PEG
-
P/S
385.1x
P/FCF
-
EV/EBITDA
-
ROIC
-29.0%
Gross margin
100.0%
Net margin
-6,388.2%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-
Beta
1.62
Free float
92.2%

About the company

Palisade Bio, Inc. (PALI) is a biotechnology company focused on the development of novel drugs and therapeutic approaches in the field of gastrointestinal diseases and rare metabolic disorders. The company is developing drugs and therapies that have the potential to alleviate health issues and improve the quality of life for patients suffering from these conditions. Palisade Bio emphasizes innovation and utilizes modern technologies and scientific knowledge to discover new treatment options. Their goal is to bring new drugs and therapies to the market that can make a real difference and enhance patient care. Palisade Bio is actively involved in research and clinical studies to confirm the effectiveness and safety of their products. Palisade Bio, Inc. (PALI) shares may be an attractive investment opportunity for investors interested in the biotechnology sector and seeking an investment in a company focusing on innovative therapeutic approaches in the field of gastrointestinal diseases and rare metabolic disorders.

Sector

Healthcare

Industry

Biotechnology

CEO

J. D. Finley

Employees

14

Headquarters

Denver

Valuation

Is today's price reasonable?

  • What to watch: The share price is above the Bulios Fair Price.

Growth and estimates

Is it growing, and what comes next?

  • What to watch: It missed profit estimates 4 times in the last 8 quarters.

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

  • What to watch: The company made a loss over the last 12 months.

Financial health

Can it carry its debt?

  • What speaks for it: It has no debt and holds $125.2M in cash.

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy